AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Indaptus Therapeutics (INDP) Pauses Clinical Trial Enrollment Amid Mixed Results
ByAinvest
Wednesday, Nov 12, 2025 8:24 pm ET1min read
Indaptus Therapeutics (INDP) has completed the initial phase of a clinical trial for its Decoy20 and tislelizumab combination, showing mixed results. The company's proprietary platform leverages bacteria to activate immune pathways, targeting various cancer models. Despite potential for trial expansion, patient enrollment is paused for further efficacy analysis. Indaptus Therapeutics has a market capitalization of approximately $3.01 million and reports no revenue, reflecting its pre-clinical stage status. The company's valuation metrics are not applicable, but its target price is set at $25. Analyst recommendations are cautious, and technical indicators show a bearish trend. The company is classified as a distressed stock with significant financial and operational risks.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet